Affiliation:
1. Clinical Oncology Dispensary
2. Novosibirsk Regional Clinical Oncology Center
Abstract
Due to the promising results of recent trials in the treatment of metastatic renal cell cancer (mRCC) multi-drug regimens combining immunotherapy and targeted therapy in the first line are increasingly recognized. The combinations are already included in international clinical guidelines as preferred treatment options for patients with mRCC. In particular, combination of lenvatinib and pembrolizumab demonstrated high efficacy in terms of achieving a complete response, progression-free survival with a manageable toxicity profile. All adverse events on this therapy are predictable and quite well controlled. We report on our own experience of using lenvatinib plus pembrolizumab combination therapy on the example of two clinical cases of patients with intermediate prognosis mRCC.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference15 articles.
1. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE‑426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2020 Dec; 21 (12): e553]. Lancet Oncol. 2020; 21 (12): 1563–1573. DOI: 10.1016/S1470–2045(20)30436–8.
2. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020; 31 (8): 1030–1039. DOI: 10.1016/j.annonc.2020.04.010.
3. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020; 5 (6): e001079. DOI: 10.1136/esmoopen-2020–001079.
4. Motzer RJ, Porta C, Eto M, et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol. 2021; 39 (suppl 6): 269. DOI: 10.1200/JCO.2021.39.6_suppl.269.
5. Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study [published online ahead of print, 2022 Apr 27]. Lancet Oncol. 2022; S 1470–2045 (22) 00212–1. DOI: 10.1016/S 1470–2045 (22)00212–1.